^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JNJ-6358

i
Other names: JNJ-6358, JNJ 78306358, JNJ-78306358
Associations
Company:
J&J, Zymeworks
Drug class:
CD3 agonist, HLA G inhibitor
Related drugs:
Associations
4ms
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors. (PubMed, Cancer Immunol Immunother)
JNJ-78306358 showed pharmacodynamic effects with induction of cytokines and T cell activation. JNJ-78306358 was associated with CRS-related toxicities including increased transaminases and pneumonitis which limited its dose escalation to potentially efficacious levels. Trial registration number ClinicalTrials.gov (No. NCT04991740).
Journal • Metastases
|
HLA-G (Major Histocompatibility Complex, Class I, G)
|
Actemra IV (tocilizumab) • JNJ-6358
over1year
Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor (ESMO 2023)
CRS was G1 or G2 and responded to tocilizumab. Considering the CRS-related toxicities and the ADA formation, the Sponsor decided to halt dose escalation. No recommended phase 2 dose was determined.
Clinical • Metastases
|
HLA-G (Major Histocompatibility Complex, Class I, G)
|
Actemra IV (tocilizumab) • JNJ-6358
over1year
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
P1, N=39, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Feb 2023 | Trial primary completion date: Feb 2024 --> Feb 2023
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR
|
JNJ-6358
almost2years
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
P1, N=39, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=140 --> 39
Enrollment closed • Enrollment change • Metastases
|
EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR
|
JNJ-6358
2years
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2024 --> Jan 2025
Trial completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR
|
JNJ-6358
over2years
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2024 --> Aug 2024
Trial completion date
|
EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR
|
JNJ-6358
3years
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
P1, N=140, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
Enrollment open
|
EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR
|
JNJ-6358
over3years
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov)
P1, N=140, Not yet recruiting, Janssen Research & Development, LLC
New P1 trial
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
JNJ-6358